Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of Sacituzumab Tirumotecan plus Toripalimab in first-line PD-L1 positive unresectable a/mTNBC
ChiCTR2500106813Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in breast cancer, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Objective response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500106813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106813.